Form 4: Beauty Health Director Stephen Fanning Granted Over 73,000 Restricted Stock Units

Stephen J. Fanning, a Director of The Beauty Health Company, was granted 73,051 Class A Common Stock Restricted Stock Units, increasing his beneficial ownership to 527,283 shares.

Summary

• Stephen J. Fanning, a Director of The Beauty Health Company (SKIN), was the reporting person for this transaction.
• The transaction involved the acquisition of 73,051 shares of Class A Common Stock.
• This acquisition was in the form of a grant of Restricted Stock Units (RSUs).
• Following this transaction, Stephen J. Fanning beneficially owns a total of 527,283 shares of Class A Common Stock.
• The RSUs are set to vest on the earlier of the one-year anniversary of the grant or the date of the 2026 Annual Meeting of Stockholders, contingent upon Mr. Fanning's continued service as a member of the Company's board of directors.
• The transaction date for the RSU grant was June 16, 2025.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating alignment of interests and retention, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with those of shareholders, incentivizing long-term performance and retention.
• The increase in beneficial ownership by a director can be seen as a demonstration of confidence in the company's future prospects.

Risks

• The vesting of the Restricted Stock Units is contingent upon Stephen J. Fanning's continued service as a director through the specified vesting dates, meaning the shares are not guaranteed if his service ceases prematurely.

Future Outlook

The vesting schedule for the granted Restricted Stock Units indicates a future commitment from the director, aligning their incentives with the company's long-term performance through at least the 2026 Annual Meeting.

Industry Context

This Form 4 filing details a routine equity compensation event for a director, which is a standard practice across publicly traded companies, including those in the beauty and health industry. Such grants are designed to align the interests of company leadership with shareholder value creation and to incentivize long-term retention.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors is a common and widely accepted practice across various industries, including the beauty and health sector, as it directly links director compensation to the company's stock performance.
• The specific number of units granted would typically be benchmarked against compensation practices for directors at peer companies of similar size and market capitalization within the beauty and health industry, though this document does not provide such comparative data.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with shareholder value, as the value of the compensation is tied to the company's stock performance.
• Management/Employees: This transaction reinforces the company's existing compensation framework for key personnel and board members, potentially influencing retention and motivation.

Next Steps

• The granted RSUs will vest on the earlier of the one-year anniversary of the grant (June 16, 2026) or the date of the 2026 Annual Meeting of Stockholders, provided Stephen J. Fanning continues his service as a director.

Key Dates

Recommendation

Keywords

Beauty Health Company, SKIN, Stephen J. Fanning, Form 4, SEC filing, Restricted Stock Units, RSUs, Director compensation, Insider ownership, Equity grant